Asset
ELOSULFASE ALFA
BioMarin Pharmaceutical Inc. Common Stock
Revenue
No revenue reported in loaded filings.
Clinical trials (6)
| NCT ID | Phase | Status | Start | Completion | Sponsor name | Title |
|---|---|---|---|---|---|---|
| NCT01242111 | phase1_2 | terminated | 2010-11-01 | 2014-07-01 | BioMarin Pharmaceutical | A Study to Evaluate the Long-Term Efficacy and Safety of BMN 110 in Patients With Mucopolysaccharidosis IVA (Morquio A Syndrome) |
| NCT00884949 | phase1_2 | completed | 2009-04-01 | 2011-02-01 | BioMarin Pharmaceutical | A Study to Evaluate the Safety, Tolerability and Efficacy of BMN 110 in Subjects With Mucopolysaccharidosis IVA |
| NCT01966029 | phase3 | completed | 2013-07-01 | 2016-07-01 | BioMarin Pharmaceutical | BMN 110 Phase 3B in Australian Patients |
| NCT01697319 | phase2 | terminated | 2012-08-01 | 2014-10-01 | BioMarin Pharmaceutical | Efficacy and Safety Study of BMN 110 for Morquio A Syndrome Patients Who Have Limited Ambulation |
| NCT01609062 | phase2 | terminated | 2012-04-01 | 2014-11-01 | BioMarin Pharmaceutical | Safety and Exercise Study of Two Doses of BMN 110 for Morquio A Syndrome |
FDA applications (1)
| Application | Type | Applicant |
|---|---|---|
| BLA 125460 | BLA | BioMarin Pharmaceutical Inc. |
Marketed products (1)
- VIMIZIM